Fluoxetine
- Generic Name
- Fluoxetine
- Brand Names
- Prozac, Sarafem, Symbyax
- Drug Type
- Small Molecule
- Chemical Formula
- C17H18F3NO
- CAS Number
- 54910-89-3
- Unique Ingredient Identifier
- 01K63SUP8D
- Background
Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies.
- Indication
Fluoxetine is indicated for both acute and maintenance treatment of major depressive disorder, obsessive compulsive disorder, and bulimia nervosa; however, it is only indicated for acute treatment of panic disorder independent of whether agoraphobia is present. Fluoxetine may also be used in combination with olanzapine to treat depression related to Bipolar ...
- Associated Conditions
- Alcohol Dependency, Anorexia Nervosa (AN), Bulimia Nervosa, Cataplexy, Depression, Major Depressive Disorder (MDD), Major depressive disorder, recurrent episode, Myoclonus, Obesity, Obsessive Compulsive Disorder (OCD), Panic Disorder With Agoraphobia, Panic disorder without agoraphobia, Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD)
- Associated Therapies
- Maintenance therapy
Combination Chemotherapy Plus Fluoxetine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-07-04
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 21
- Registration Number
- NCT00005850
- Locations
- 🇺🇸
Memorial Regional Hospital Comprehensive Cancer Center, Hollywood, Florida, United States
🇺🇸Helen and Harry Gray Cancer Institute at Good Samaritan Medical Center, West Palm Beach, Florida, United States
🇺🇸Fort Wayne Medical Oncology and Hematology, Incorporated, Fort Wayne, Indiana, United States
Relapse Prevention for Bipolar Type-II Disorder
- Conditions
- First Posted Date
- 2002-09-05
- Last Posted Date
- 2015-10-06
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 180
- Registration Number
- NCT00044616
- Locations
- 🇺🇸
Depression Research Unit, Univ Penn, Philadelphia, Pennsylvania, United States
Treatment of Childhood Social Phobia
- Conditions
- Interventions
- First Posted Date
- 2002-08-12
- Last Posted Date
- 2013-08-01
- Lead Sponsor
- University of Central Florida
- Target Recruit Count
- 139
- Registration Number
- NCT00043537
- Locations
- 🇺🇸
Maryland Center for Anxiety Disorders, University of Maryland, College Park, Maryland, United States
The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression
- Conditions
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2006-07-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 600
- Registration Number
- NCT00035321
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St. John, Canada
Study of Fluoxetine in Adults With Autistic Disorder
- Conditions
- First Posted Date
- 2001-12-07
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 48
- Registration Number
- NCT00027404
- Locations
- 🇺🇸
Mount Sinai School of Medicine, New York, New York, United States
Treatment of SSRI-Resistant Depression In Adolescents (TORDIA)
- Conditions
- Interventions
- First Posted Date
- 2001-07-12
- Last Posted Date
- 2014-03-12
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 334
- Registration Number
- NCT00018902
- Locations
- 🇺🇸
Kaiser Permanente Center for Health Research, Portland, Oregon, United States
🇺🇸University of California at Los Angeles, Los Angeles, California, United States
🇺🇸Brown University, Providence, Rhode Island, United States
Effect of Antidepressants on Back Pain
- Conditions
- Interventions
- First Posted Date
- 2001-07-05
- Last Posted Date
- 2012-06-05
- Lead Sponsor
- US Department of Veterans Affairs
- Target Recruit Count
- 130
- Registration Number
- NCT00018200
- Locations
- 🇺🇸
VA San Diego Healthcare System, San Diego, San Diego, California, United States
Fluoxetine as a Quit Smoking Aid for Depression-Prone Smokers
- Conditions
- Interventions
- First Posted Date
- 2001-07-05
- Last Posted Date
- 2009-03-02
- Lead Sponsor
- US Department of Veterans Affairs
- Target Recruit Count
- 247
- Registration Number
- NCT00018174
- Locations
- 🇺🇸
Edward Hines, Jr. VA Hospital, Hines, Illinois, United States
Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
- Conditions
- Interventions
- First Posted Date
- 2001-07-02
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 2530
- Registration Number
- NCT00018057
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Effect of Fluoxetine (Prozac) on Domestic Violence
- Conditions
- First Posted Date
- 2001-03-01
- Last Posted Date
- 2017-07-02
- Target Recruit Count
- 104
- Registration Number
- NCT00011765
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.